Cover Image

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer

Abstract Ovarian cancer is the most lethal gynaecologic malignancy. Although there are various subtypes of ovarian cancer, high-grade serous ovarian cancer (HGSOC) accounts for 70% of ovarian cancer deaths. Chemoresistance is the primary reason for the unfavourable prognosis of HGSOC. Kallistatin (K...

Full description

Saved in:

Bibliographic Details
Main Authors:	Huan Wu (Author), Rongrong Li (Author), Zhiwei Zhang (Author), Huiyang Jiang (Author), Hanlin Ma (Author), Cunzhong Yuan (Author), Chenggong Sun (Author), Yingwei Li (Author), Beihua Kong (Author)
Format:	Book
Published:	BMC, 2019-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
by: Huan Wu, et al.
Published: (2020)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
by: Reem Abdallah, et al.
Published: (2023)

Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer
by: Michelle Greenman, et al.
Published: (2024)

Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
by: Daniela Criscuolo, et al.
Published: (2022)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
by: Zheng Feng, et al.
Published: (2023)

Modern strategies of platinum resistance overcoming in patients with the serous ovarian cancer
by: Andriy Rybin
Published: (2018)

Modern strategies of platinum resistance overcoming in patients with the serous ovarian cancer
by: Andriy Rybin
Published: (2018)

Role of human Kallistatin in glucose and energy homeostasis in mice
by: Leontine Sandforth, et al.
Published: (2024)

Kallistatin leads to cognition impairment via downregulating glutamine synthetase
by: Yanlan Long, et al.
Published: (2024)

Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis
by: Zhiyun Cheng, et al.
Published: (2015)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
by: Kenneth P. Nephew (Ed.)
Published: (2019)

Proteome profiling of low grade serous ovarian cancer
by: Haniyeh Bashi zadeh fakhar, et al.
Published: (2019)

Frequency of serous tubal intraepithelial carcinoma (STIC) in patients with high grade serous ovarian cancer
by: Jung Mi Byun, et al.
Published: (2023)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
by: Renan Ribeiro e Ribeiro, et al.
Published: (2021)

Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
by: Rami Vanguri, et al.
Published: (2022)

Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma
by: Rosie T. Jiang, et al.
Published: (2017)

Ovarian collision tumour consisting of a fibroma and a serous cystadenoma: A case report
by: Anwar Rjoop, et al.
Published: (2024)

Cardiophrenic lymph node metastasis in low-grade serous ovarian adenocarcinoma
by: Tasha Serna-Gallegos, et al.
Published: (2017)

Digital pathology-based study of cell- and tissue-level morphologic features in serous borderline ovarian tumor and high-grade serous ovarian cancer
by: Jun Jiang, et al.
Published: (2021)

Durable response to hormonal therapy in a patient with rapidly progressive low-grade serous ovarian cancer: A case report
by: Catherine H. Watson, et al.
Published: (2020)

A rare ovarian hilus cell tumour accompanying bilateral serous cystadenomas: report of a case
by: Haider Ali Malakzai, et al.
Published: (2021)

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
by: Elizabeth K. Lee, et al.
Published: (2020)

Targeted therapy in high grade serous ovarian Cancer: A literature review
by: Kaitlyn Dinkins, et al.
Published: (2024)

Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
by: Lu Zhang, et al.
Published: (2021)

Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer
by: A. W. Adamson, et al.
Published: (2023)

Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse
by: Yana Ma, et al.
Published: (2023)

Characteristics of Extracellular Vesicles from a High-Grade Serous Ovarian Cancer Cell Line Derived from a Platinum-Resistant Patient as a Potential Tool for Aiding the Prediction of Responses to Chemotherapy
by: Katarina Černe, et al.
Published: (2023)

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
by: Zibi Marchocki, et al.
Published: (2022)

Paraneoplastic opsoclonus-myoclonus syndrome as a presentation of high grade serous ovarian cancer
by: Kimberly T. Stewart, et al.
Published: (2019)

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo
by: Zhi-Ying Qi, et al.
Published: (2019)

Retraction Note: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo
by: Zhi-Ying Qi, et al.
Published: (2023)

Malignant peritoneal mesothelioma in a woman with bilateral ovarian serous borderline tumour: Potential interactions between the two diseases
by: Lorena Losi, et al.
Published: (2018)

High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature
by: Yuichiro Hatano, et al.
Published: (2019)

Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1
by: Eric J. Norris, et al.
Published: (2018)

The molecular prognostic score, a classifier for risk stratification of high-grade serous ovarian cancer
by: Siddik Sarkar, et al.
Published: (2024)

Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer
by: Shashank Sama, et al.
Published: (2024)

Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer
by: Julia McAdams, et al.
Published: (2024)

Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer
by: Hua Yang, et al.
Published: (2022)

Disparities in treatment modalities and survival among older patients with high-grade serous ovarian cancer
by: Yan Cai, et al.
Published: (2024)

Clinical outcomes of immunohistochemistry of the p53 Staining pattern in high-grade serous ovarian carcinoma
by: Panarat Orachum, et al.
Published: (2022)